Health Technology Assessment

Health technology assessment (HTA) is the systematic evaluation of health technologies—drugs, devices, diagnostics, procedures, and increasingly digital tools and public-health programmes—to inform decisions about whether and how they should be used and paid for.

10 frameworks, from 1970 to today · Health Economics · Economics

still a working view ended · each leads to its entry below

Overview

Health technology assessment (HTA) is the systematic evaluation of health technologies—drugs, devices, diagnostics, procedures, and increasingly digital tools and public-health programmes—to inform decisions about whether and how they should be used and paid for. Its practitioners ask a deceptively simple question: given finite budgets, does this technology deliver enough benefit to justify its cost, and if so, for whom? The stakes are concrete. When a national insurer decides whether to cover a new cancer drug, or a hospital decides whether to adopt a surgical robot, someone is deciding how a fixed pool of money becomes health. HTA is the machinery that has grown up to make those decisions defensible rather than arbitrary.

From Clinical Trials to Economic Evaluation: The Postwar Roots

The intellectual foundations lie in the mid-twentieth century, when two streams converged. One was the randomised controlled trial (RCT), which by the 1960s had become the gold standard for establishing whether a treatment works at all. The other was welfare economics, which supplied the idea that public spending should be judged by the value of what it buys relative to its opportunity cost—the health forgone elsewhere when money is spent here.

The pivotal figure was Alan Williams, a British health economist who in the 1970s and 1980s argued that health services should be evaluated in terms of cost per unit of health gain, not cost per case or per bed-day. His work helped establish the discipline of health economics in Britain and gave HTA its central metric. In the United States, the Office of Technology Assessment (OTA), created by Congress in 1972, pioneered the systematic appraisal of medical technologies for policymakers, though its remit was broader than economics and it was abolished in 1995. The term "health technology assessment" itself gained currency in the 1980s, as European governments began building formal bodies to advise on coverage.

The Cost-Effectiveness Toolkit

The core analytic method that emerged is cost-effectiveness analysis (CEA): comparing the incremental cost of a technology with its incremental health benefit, usually expressed as cost per life-year gained or per case detected. Its logic is comparative—a technology is judged against the best available alternative, not against doing nothing—and its output is a ratio, the incremental cost-effectiveness ratio (ICER), which states how much extra money buys one extra unit of health.

A crucial refinement was cost-utility analysis (CUA), which measures benefit in quality-adjusted life-years (QALYs)1. A QALY combines length of life with quality of life on a single scale: one year in perfect health equals 1.0, a year with moderate disability might equal 0.62. The QALY was developed in the 1970s and 1980s by researchers including Milton Weinstein and George Torrance, building on earlier work on health-status measurement. Its appeal is that it allows comparison across entirely different diseases—a hip replacement and a cancer drug can be judged on the same yardstick. The QALY remains the dominant outcome measure in HTA, though it has always attracted criticism for how it values different kinds of health states and different people.

Decision-Analytic Modelling: Simulating the Future

Trials are short and narrow; decisions are long and broad. Decision-analytic modelling filled the gap. Rather than relying only on observed trial data, analysts built mathematical models—decision trees, Markov models, and later discrete-event simulations—that projected costs and outcomes over a lifetime or a budget period, synthesising evidence from many sources. A Markov model, for instance, represents a patient moving among health states (well, sick, dead) with probabilities drawn from trials and epidemiology, and accumulates costs and QALYs over time. This made it possible to evaluate technologies before long-term data existed, and to conduct sensitivity analysis—testing how conclusions change when assumptions vary. The approach was codified in influential textbooks and guidelines from the 1990s onward, notably the work of Michael Drummond and colleagues, whose Methods for the Economic Evaluation of Health Care Programmes became a standard reference.

Evidence Synthesis and the Systematic Review

HTA rests on evidence, and the evidence base is vast and uneven. Systematic review and evidence synthesis became the method for assembling it: a pre-specified, reproducible search and appraisal of all relevant studies, often culminating in a meta-analysis that pools results statistically3. The Cochrane Collaboration, founded in 1993, institutionalised this approach for health care, and HTA bodies adopted it as a required first step. The logic is that a coverage decision should rest on the totality of evidence, not on a single favourable trial—and that the process of finding and weighing evidence should itself be transparent and replicable.

National Bodies and the Rise of Formal Appraisal

The 1990s and 2000s saw HTA institutionalised. The most influential example is the UK's National Institute for Health and Care Excellence (NICE), established in 1999. NICE introduced a formal, published appraisal process with a cost-effectiveness threshold: technologies were generally recommended if their ICER fell below a stated range (initially around £20,000–£30,000 per QALY). The threshold made the opportunity-cost logic explicit—below it, a technology was deemed worth buying; above it, the health forgone elsewhere outweighed the gain. NICE's model spread: Australia's Pharmaceutical Benefits Advisory Committee had pioneered formal economic evaluation for drugs in the early 1990s, and Canada, Germany, and many other countries built their own bodies with varying methods and thresholds.

Value-based pricing and threshold appraisal grew from this. The idea is that a technology's price should reflect the value it delivers—its health gain relative to cost—rather than what the market will bear. Thresholds operationalise this: they define what the system is willing to pay per QALY. The approach is powerful but contested, because the "right" threshold depends on the marginal productivity of the health system, which is hard to measure and varies by context.

Budget Impact and the Affordability Question

Cost-effectiveness asks whether a technology is worth its price; budget impact analysis asks whether the system can afford it this year. A technology can be highly cost-effective and still blow a hole in a fixed annual budget if it is expensive per patient and used widely. Budget impact analysis projects the financial consequences of adoption over a short horizon, typically one to five years, accounting for uptake rates and offsets. It became a standard companion to cost-effectiveness in reimbursement dossiers, particularly for pharmaceuticals, because payers must plan cash flow as well as value.

Multi-Criteria Decision Analysis and the Broadening of Value

Not everything that matters fits into a QALY. Multi-criteria decision analysis (MCDA) emerged as a structured way to weigh multiple dimensions—severity of disease, unmet need, equity, innovation, budget impact—explicitly rather than implicitly4. Practitioners assign scores and weights to criteria and combine them into a ranking. MCDA has been used in several HTA contexts, though its uptake has been uneven; critics note that weights are themselves value judgements, and that the method can obscure as much as it clarifies if poorly applied.

A related development is extended value and severity-weighted assessment. Some systems give extra weight to health gains for people with severe conditions, or to technologies addressing unmet need, rather than treating all QALYs as equal. The Netherlands and Norway, among others, have experimented with severity weighting, and debates about "extended value" ask whether HTA should recognise dimensions beyond health gain—such as equity, caregiver burden, or the value of hope. These debates are live and unresolved; the QALY remains the anchor, but its monopoly is contested.

Real-World Evidence and the Data Revolution

Trials are artificial. Real-world evidence (RWE)—data from registries, electronic health records, claims databases, and observational studies—offers a picture of how technologies perform in ordinary practice, among patients often excluded from trials. HTA bodies have increasingly accepted RWE for specific purposes: confirming long-term safety, evaluating technologies in rare diseases where trials are impractical, and monitoring performance after coverage. The challenge is causal inference: observational data are confounded, and HTA must judge whether an RWE study credibly identifies a treatment effect. Methods from econometrics and epidemiology—propensity scoring, instrumental variables, difference-in-differences—have migrated into HTA for this reason, and regulatory agencies alongside HTA bodies have issued guidance on when RWE is fit for purpose.

The Present: Institutionalised, Contested, Expanding

Today HTA is a global enterprise. Nearly every high-income country has a formal body, and middle-income countries are building them. Methods have converged around cost-effectiveness and cost-utility analysis, decision-analytic modelling, systematic review, and budget impact, with national variation in thresholds, weighting, and process. The field's open questions are substantive: how to value health states and whose preferences count; whether thresholds should be explicit and how to set them; how to incorporate equity and severity; how to handle uncertainty and rare diseases; and how to integrate real-world evidence credibly. The machinery built over five decades is now the ordinary language of coverage decisions—and the arguments about what it should measure are the field's continuing history.

References

  1. Cost–utility analysis, Wikipedia
  2. Quality-adjusted life year, Wikipedia
  3. Systematic review, Wikipedia
  4. Multiple-criteria decision analysis, Wikipedia

The frameworks of Health Technology Assessment

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1970-Present

    Cost-Effectiveness Analysis

    Is this technology worth its cost in health gained?

    Fly to its tower in Nousfarer

  2. 1980-Present

    Cost-Utility Analysis

    How much health gain per pound does a treatment buy?

    Fly to its tower in Nousfarer

  3. 1990-Present

    Decision-Analytic Modelling

    What will costs and outcomes be over a lifetime?

    Fly to its tower in Nousfarer

  4. 1990-Present

    Systematic review

    What does the totality of evidence show?

    Fly to its tower in Nousfarer

  5. 1995-Present

    Budget Impact Analysis

    Can the health system afford this technology this year?

    Fly to its tower in Nousfarer

  6. 1999-Present

    Threshold-Based Appraisal

    What price per unit of health is acceptable?

    Fly to its tower in Nousfarer

  7. 2000-Present

    Multiple-criteria decision analysis

    How should many competing criteria be weighed together?

    Fly to its tower in Nousfarer

  8. 2000-Present

    Value-Based Pricing

    What price reflects the value delivered?

    Fly to its tower in Nousfarer

  9. 2005-Present

    Extended Value and Severity-Weighted Assessment

    Should health gains count more for the severely ill?

    Fly to its tower in Nousfarer

  10. 2010-Present

    Real world evidence

    How do technologies perform in ordinary practice?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Cost-Effectiveness AnalysisCost-Utility AnalysisDecision-Analytic ModellingSystematic reviewBudget Impact AnalysisThreshold-Based AppraisalMultiple-criteria decision analysisValue-Based PricingExtended Value and Severity-Weighted …Real world evidence

Beyond the field

Where Health Technology Assessment's ideas came from in other fields, and what they led to there: the strongest 12 of 43 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Health Technology Assessment is a planet in Nousfarer

Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.

Land on Health Technology Assessment

Related fields

Fields its ideas are linked to

More in Health Economics

See where Health Technology Assessment sits on the Map of Human Knowledge